Zipalertinib在携带EGFR外显子20插入突变的非小细胞肺癌患者中的安全性、耐受性和抗肿瘤活性
这项1/2a期研究纳入73例既往接受过铂类化疗的复发或转移性EGFR外显子20插入突变非小细胞肺癌患者,接受zipalertinib 30、45、65、100和150 mg口服每日两次治疗。最常见治疗相关不良事件为皮疹(80%)、甲沟炎(32%)、腹泻(30%)和疲乏(21%);在100 mg每日两次及以下剂量未观察到3级或以上药物相关皮疹或腹泻。确认部分缓解见于28/73(38.4%)可评估患者,100 mg每日两次组为16/39(41%)。
要点
- zipalertinib在重度经治EGFR外显子20插入突变NSCLC中显示初步抗肿瘤活性。
- 确认部分缓解见于28/73(38.4%)可评估患者,100 mg每日两次组为16/39(41%)。
- 100 mg每日两次及以下剂量未观察到3级或以上药物相关皮疹或腹泻。
核心结论
- zipalertinib在重度经治EGFR外显子20插入突变NSCLC患者中具有令人鼓舞的初步抗肿瘤活性,安全性可接受,包括高级别腹泻和皮疹发生率低。
研究设计与样本
- 这项1/2a期研究纳入73例既往接受过铂类化疗的复发或转移性EGFR外显子20插入突变非小细胞肺癌患者。
- 患者接受zipalertinib 30、45、65、100和150 mg口服每日两次治疗。
主要发现
- 患者主要为女性(56%),中位年龄64岁,既往系统治疗中位数为2线(范围1-9)。
- 36%的患者既往接受过非外显子20插入EGFR酪氨酸激酶抑制剂,3/73(4.1%)患者既往接受过EGFR外显子20插入酪氨酸激酶抑制剂。
- 任何级别最常见治疗相关不良事件包括皮疹(80%)、甲沟炎(32%)、腹泻(30%)和疲乏(21%)。
- 在100 mg每日两次或以下剂量未观察到3级或以上药物相关皮疹或腹泻。
- 所有测试的zipalertinib剂量水平均观察到客观缓解,确认部分缓解见于28/73(38.4%)可评估患者,100 mg每日两次组为16/39(41%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine scaffold leading to enhanced selectivity for EGFR ex20ins-mutant versus WT EGFR with potent inhibition of cell growth in EGFR ex20ins-positive cell lines. METHODS: This phase 1/2a study of zipalertinib enrolled patients with recurrent or metastatic EGFR ex20ins-mutant non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. RESULTS: Seventy-three patients were treated with zipalertinib at dose levels including 30, 45, 65, 100, and 150 mg orally twice a day. Patients were predominantly female (56%), had a median age of 64 years, and were heavily pretreated (median previous systemic therapies 2, range 1-9). Thirty six percent of patients had received previous non-ex20ins EGFR TKIs and 3/73 (4.1%) patients received previous EGFR ex20ins TKIs. The most frequently reported treatment-related adverse events of any grade included rash (80%), paronychia (32%), diarrhea (30%), and fatigue (21%). No cases of grade 3 or higher drug-related rash or diarrhea were observed at 100 mg twice a day or below. Objective responses occurred across all zipalertinib dose levels tested, with confirmed partial response (PR) observed in 28/73 (38.4%) response-evaluable patients. Confirmed PRs were seen in 16/39 (41%) response-evaluable patients at the dose of 100 mg twice a day. CONCLUSION: Zipalertinib has encouraging preliminary antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile, including low frequency of high-grade diarrhea and rash.
引用
- Piotrowska Z, Tan DS, Smit EF, et al. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. J Clin Oncol. 2023. PMID: 37384848. doi:10.1200/JCO.23.00152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。